|
|
Article: Celgene Corporation Reports Second Quarter Results; Thalomid(R) Product Sales Increase More Than 50 Percent.
- Article from:
- PR Newswire
- Article date:
- August 11, 1999
CopyrightCOPYRIGHT 1999 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WARREN, N.J., Aug. 11 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) today announced its financial results for the second quarter ended June 30, 1999. Net revenue was $5.8 million, reflecting $5.3 million in product sales of Thalomid(R) (thalidomide) and $495,000 of revenue from research contracts. The Company had no revenue for the comparable period in 1998. The $5.3 million in Thalomid sales represents a 51 percent increase over the preceding quarter. The net loss from continuing operations for the second quarter of 1999 was $6.2 million, or $0.37 per share, compared to a net loss of $8.8 million, or $0.55 per share, in the comparable 1998 period.
For the ...